University of Iowa Interventional Psychiatry Service Patient Registry

Summary

The purpose of this study is to examine the effects of interventional/procedural therapies for treatment-resistant depression (TRD) and Obsessive-Compulsive Disorder (OCD). These treatments include electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), racemic ketamine infusion and intranasal esketamine insufflation. The investigators will obtain various indicators, or biomarkers, of a depressed individuals' state before, during, and/or after these treatments. Such biomarkers include neurobehavioral testing, neuroimaging, electroencephalography, cognitive testing, vocal recordings, epi/genetic testing, and autonomic nervous system measures (i.e. "fight-or-flight" response). The results obtained from this study may provide novel antidepressant treatment response biomarkers, with the future goal of targeting a given treatment to an individual patient ("personalized medicine").

Conditions

• Treatment Resistant Depression
• Major Depressive Episode
• Major Depression
• Major Depressive Disorder
• Bipolar Disorder
• Bipolar Depression
• Obsessive-Compulsive Disorder

Interventions

DEVICE

Electroconvulsive Therapy (ECT)

ECT for the treatment of treatment-resistant depression OR Bipolar Disorder in an active major depressive episode

DEVICE

Transcranial Magnetic Stimulation (TMS)

TMS for the treatment of treatment-resistant depression in an active major depressive episode

DRUG

Ketamine

Intravenous ketamine infusion for the treatment of treatment-resistant depression in an active major depressive episode

DRUG

Esketamine

Intranasal esketamine insufflation for the treatment of treatment-resistant depression in an active major depressive episode

DEVICE

Deep Transcranial Magnetic Stimulation (dTMS)

TMS for the treatment of OCD

Sponsors & Collaborators

• Mark Niciu

  lead OTHER

Principal Investigators

• Mark J Niciu, M.D., Ph. D. · University of Iowa Hospitals & Clinics

• Nicholas T Trapp, M.D., M.S. · University of Iowa Hospitals & Clinics

Eligibility

Min Age

18 Years

Max Age

99 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2020-11-02

Primary Completion

2050-08-31

Completion

2050-08-31

FDA Drug

Yes

FDA Device

Yes

Countries

• United States

Study Locations